Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07163650 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of Sep 1, 2025 to Sep 16, 2025 Eligibility criteria expanded, about 516 words · Secondary endpoints: 4 to 7 · Study description expanded, about 54 words · 1 morev2 Show 4 more changesShow less
    • Eligibility criteria expanded, about 516 words
    • Secondary endpoints: 4 to 7
    • Study description expanded, about 54 words
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial aims to evaluate the weight-loss efficacy and safety of efsubaglutide alfa in patients who remain obese 6 months after metabolic surgery.
Trial Details
NCT Number NCT07163650
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Obesity, Weight Loss, Metabolic Surgery
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov